Experts in Drug Product Development

Formulation scientists know the challenge of excipient preselection: trial-and-error, time-consuming experiments, and uncertainty. What if there was a way to reduce risk,minimize bias, and improve formulation outcomes—before even stepping into the lab?

Leukocare, a leading provider of drug product and formulation development services, is pleased to announce the appointment of Dr. Cornelius Pompe as its new Chief Operating Officer (COO). In his new position Cornelius Pompe will play a pivotal role in the company’s continued growth as it expands its cutting-edge services to the pharmaceutical and biotechnology industries.
With a deep focus on harnessing the power of data science, bioinformatics, and advanced analytics, Leukocare helps drug developers optimize their drug product formulations and respective processes, improve efficiency, and reduce time-to-market. As COO, Cornelius Pompe will be responsible for the day-to-day operational management of the company. Moreover, he will lead efforts to scale the company’s service offerings, enhance operational excellence, and deliver advanced solutions by extending Leukocare’s data science toolbox to meet the evolving needs of the industry.